Eli Lilly and Co Company Profile (NYSE:LLY)

About Eli Lilly and Co (NYSE:LLY)

Eli Lilly and Co logoEli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2016, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:LLY
  • CUSIP: 53245710
  • Web: www.lilly.com
Capitalization:
  • Market Cap: $82.44 billion
  • Outstanding Shares: 1,056,300,000
Average Prices:
  • 50 Day Moving Avg: $81.32
  • 200 Day Moving Avg: $78.34
  • 52 Week Range: $64.18 - $86.72
P/E:
  • Trailing P/E Ratio: 37.74
  • Foreward P/E Ratio: 17.90
  • P/E Growth: 1.54
Sales & Book Value:
  • Annual Revenue: $21.59 billion
  • Price / Sales: 3.82
  • Book Value: $13.28 per share
  • Price / Book: 5.88
Dividend:
  • Annual Dividend: $2.08
  • Dividend Yield: 2.7%
Profitability:
  • EBIDTA: $5.64 billion
  • Net Margins: 12.90%
  • Return on Equity: 24.74%
  • Return on Assets: 10.30%
Debt:
  • Debt-to-Equity Ratio: 0.56%
  • Current Ratio: 1.62%
  • Quick Ratio: 1.15%
Misc:
  • Average Volume: 3.93 million shs.
  • Beta: 0.3
  • Short Ratio: 2.41
 

Frequently Asked Questions for Eli Lilly and Co (NYSE:LLY)

What is Eli Lilly and Co's stock symbol?

Eli Lilly and Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and Co pay dividends? What is the dividend yield for Eli Lilly and Co?

Eli Lilly and Co announced a quarterly dividend on Monday, May 1st. Shareholders of record on Monday, May 15th will be paid a dividend of $0.52 per share on Friday, June 9th. This represents a $2.08 annualized dividend and a yield of 2.66%. The ex-dividend date is Thursday, May 11th. View Eli Lilly and Co's Dividend History.

How were Eli Lilly and Co's earnings last quarter?

Eli Lilly and Co (NYSE:LLY) posted its quarterly earnings data on Tuesday, April, 25th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.96 by $0.02. The company earned $5.23 billion during the quarter, compared to analyst estimates of $5.22 billion. Eli Lilly and Co had a return on equity of 24.74% and a net margin of 12.90%. The business's revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.83 EPS. View Eli Lilly and Co's Earnings History.

When will Eli Lilly and Co make its next earnings announcement?

Eli Lilly and Co is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Eli Lilly and Co.

What guidance has Eli Lilly and Co issued on next quarter's earnings?

Eli Lilly and Co issued an update on its FY17 earnings guidance on Tuesday, April, 25th. The company provided EPS guidance of $4.05-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.10. The company issued revenue guidance of $21.8-22.3 billion, compared to the consensus revenue estimate of $22.10 billion.

Where is Eli Lilly and Co's stock going? Where will Eli Lilly and Co's stock price be in 2017?

17 analysts have issued 12-month target prices for Eli Lilly and Co's stock. Their forecasts range from $73.00 to $100.00. On average, they expect Eli Lilly and Co's share price to reach $88.21 in the next twelve months. View Analyst Ratings for Eli Lilly and Co.

Who are some of Eli Lilly and Co's key competitors?

Who owns Eli Lilly and Co stock?

Eli Lilly and Co's stock is owned by a number of of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (11.87%), Vanguard Group Inc. (6.49%), BlackRock Inc. (5.89%), Primecap Management Co. CA (5.41%), Wellington Management Group LLP (5.36%) and State Street Corp (4.01%). Company insiders that own Eli Lilly and Co stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, R David Hoover, Stephen F Fry and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and Co.

Who sold Eli Lilly and Co stock? Who is selling Eli Lilly and Co stock?

Eli Lilly and Co's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Massachusetts Financial Services Co. MA, Lilly Endowment Inc., Bank of New York Mellon Corp, First American Bank, Primecap Management Co. CA, TIAA CREF Investment Management LLC and Jennison Associates LLC. Company insiders that have sold Eli Lilly and Co stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes and Susan Mahony. View Insider Buying and Selling for Eli Lilly and Co.

Who bought Eli Lilly and Co stock? Who is buying Eli Lilly and Co stock?

Eli Lilly and Co's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Beutel Goodman & Co Ltd., Vanguard Group Inc., Winslow Capital Management LLC, Renaissance Technologies LLC, Alliancebernstein L.P., Swiss National Bank and Teacher Retirement System of Texas. Company insiders that have bought Eli Lilly and Co stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and Co.

How do I buy Eli Lilly and Co stock?

Shares of Eli Lilly and Co can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Eli Lilly and Co stock cost?

One share of Eli Lilly and Co stock can currently be purchased for approximately $78.05.

Analyst Ratings

Consensus Ratings for Eli Lilly and Co (NYSE:LLY) (?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 12 Buy Ratings
Consensus Rating:Buy (Score: 2.65)
Consensus Price Target: $88.21 (13.02% upside)

Analysts' Ratings History for Eli Lilly and Co (NYSE:LLY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
5/16/2017Goldman Sachs Group IncReiterated RatingConviction-Buy -> Buy$92.00HighView Rating Details
4/29/2017BMO Capital MarketsReiterated RatingUnderperform$71.00 -> $73.00LowView Rating Details
4/29/2017Jefferies Group LLCReiterated RatingBuy$94.00 -> $92.00LowView Rating Details
4/27/2017ArgusDowngradeBuy -> Hold$64.18 -> $81.00LowView Rating Details
4/19/2017Citigroup IncBoost Price TargetBuy$92.00 -> $100.00LowView Rating Details
4/19/2017Credit Suisse Group AGReiterated RatingOutperform$87.00LowView Rating Details
4/17/2017Piper Jaffray CompaniesReiterated RatingBuy$100.00MediumView Rating Details
4/17/2017Cowen and CompanyBoost Price TargetOutperform$85.00 -> $95.00MediumView Rating Details
4/17/2017Morgan StanleyDowngradeOverweight -> Equal Weight$82.00HighView Rating Details
4/7/2017Barclays PLCBoost Price TargetOverweight$85.00 -> $90.00LowView Rating Details
3/20/2017Leerink SwannReiterated RatingOutperformLowView Rating Details
11/26/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/AView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight -> NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
9/20/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
6/15/2016SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
2/4/2016Berenberg BankBoost Price TargetBuy$105.00 -> $106.00N/AView Rating Details
12/22/2015Bank of America CorpReiterated RatingBuy$104.00 -> $108.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Eli Lilly and Co (NYSE:LLY)
Earnings by Quarter for Eli Lilly and Co (NYSE:LLY)
Earnings History by Quarter for Eli Lilly and Co (NYSE:LLY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2017        
4/25/2017Q1 17$0.96$0.98$5.22 billion$5.23 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eli Lilly and Co (NYSE:LLY)
2017 EPS Consensus Estimate: $4.14
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.98$0.98$0.98
Q2 20172$1.06$1.07$1.07
Q3 20172$1.02$1.04$1.03
Q4 20172$1.05$1.07$1.06
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Eli Lilly and Co (NYSE:LLY)
Next Dividend:6/9/2017
Annual Dividend:$2.08
Dividend Yield:2.66%
Dividend Growth:1.30% (3 Year Average)
Payout Ratio:80.62% (Trailing 12 Months of Earnings)
50.49% (Based on This Year's Estimates)
47.71% (Based on Next Year's Estimates)
Track Record:2 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Eli Lilly and Co (NYSE:LLY)

Dividend History by Quarter for Eli Lilly and Co (NYSE:LLY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Eli Lilly and Co (NYSE:LLY)
Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 75.15%
Insider Trades by Quarter for Eli Lilly and Co (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and Co (NYSE:LLY)
Insider Trades by Quarter for Eli Lilly and Co (NYSE:LLY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.00View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.68View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.39View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.00View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.30View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.76View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.39View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.20View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.08View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.84View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.00View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.00View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.00View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.10View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.78View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.74View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.40View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.00View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.00View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.83View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.00View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Eli Lilly and Co (NYSE:LLY)
Latest Headlines for Eli Lilly and Co (NYSE:LLY)
Source:
DateHeadline
americanbankingnews.com logoEli Lilly and Co (LLY) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 26 at 6:47 PM
finance.yahoo.com logoElanco Animal Health Works to Bring Products to Small Holder Farmers, Increasing Food Security in East Africa
finance.yahoo.com - May 24 at 11:06 AM
finance.yahoo.com logoAstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk
finance.yahoo.com - May 24 at 11:06 AM
americanbankingnews.com logoSanford C. Bernstein Reiterates "Outperform" Rating for Eli Lilly and Co (LLY)
www.americanbankingnews.com - May 21 at 9:28 AM
nasdaq.com logoEli Lilly CEO on Tax Reform and GOP's Health-Care Bill - Presented by: The Aol. On Network
www.nasdaq.com - May 20 at 12:02 AM
nasdaq.com logoEli Lilly is Oversold
www.nasdaq.com - May 19 at 7:00 PM
finance.yahoo.com logoEli Lilly CEO Says 'Time Is Now' for Corporate Tax Reform
finance.yahoo.com - May 19 at 7:00 PM
finance.yahoo.com logoEli Lilly CEO on Tax Reform and GOP's Health-Care Bill
finance.yahoo.com - May 19 at 7:00 PM
bizjournals.com logoUnited Therapeutics reworks deal ahead of a key patent's expiration - Washington Business Journal
www.bizjournals.com - May 19 at 10:50 AM
finance.yahoo.com logoConference Spotlights Drug Giant Donnybrooks In Cancer Treatments
finance.yahoo.com - May 19 at 10:50 AM
finance.yahoo.com logoUnited Therapeutics reworks deal ahead of a key patent's expiration
finance.yahoo.com - May 19 at 10:50 AM
americanbankingnews.com logoEli Lilly and Sees Unusually High Options Volume (LLY)
www.americanbankingnews.com - May 19 at 7:04 AM
finance.yahoo.com logoEli Lilly Stock Faces Uncertainty, Bernstein Says
finance.yahoo.com - May 17 at 6:16 PM
finance.yahoo.com logoLilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017
finance.yahoo.com - May 17 at 6:16 PM
barrons.com logoEli Lilly: Has This Bloom Begun To Wilt? - Barron's
www.barrons.com - May 16 at 6:08 PM
reuters.com logoBRIEF-3Sbio Inc enters distribution and promotion agreement with two subsidiaries of Eli Lilly
www.reuters.com - May 16 at 10:43 AM
finance.yahoo.com logoActress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom
finance.yahoo.com - May 16 at 10:43 AM
americanbankingnews.com logoEli Lilly and Co (LLY) Downgraded to Buy at Goldman Sachs Group Inc
www.americanbankingnews.com - May 16 at 8:30 AM
finance.yahoo.com logoThe prices for life-saving diabetes medications have increased again
finance.yahoo.com - May 15 at 5:44 PM
streetinsider.com logoEli Lilly & Co. (LLY) Reports Positive Results for Three Phase 3 Galcanezumab Studies
www.streetinsider.com - May 13 at 9:06 AM
finance.yahoo.com logoLilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
finance.yahoo.com - May 12 at 11:58 PM
finance.yahoo.com logoMigraine Drug From Eli Lilly Is Successful in Late-Stage Trials
finance.yahoo.com - May 12 at 11:58 PM
finance.yahoo.com logoUPDATE: Eli Lilly reports positive results in trial of migraine treatment
finance.yahoo.com - May 12 at 11:58 PM
finance.yahoo.com logo[$$] Lilly's New Migraine Drug Shows Positive Results
finance.yahoo.com - May 12 at 11:58 PM
bloomberg.com logoMigraine Drug From Eli Lilly Is Successful in Late-Stage Trials - Bloomberg
www.bloomberg.com - May 12 at 6:58 PM
finance.yahoo.com logoEli Lilly & Co. : LLY-US: Dividend Analysis : May 15th, 2017 (record date) : By the numbers : May 11, 2017
finance.yahoo.com - May 11 at 6:48 PM
businesswire.com logoWorld Lung Cancer Therapeutics Market Opportunities and Forecasts 2014-2017 & 2022: Leading Companies are Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Co, Pfizer ...
www.businesswire.com - May 10 at 10:55 PM
finance.yahoo.com logoLilly to Participate in Bernstein Strategic Decisions Conference
finance.yahoo.com - May 10 at 5:54 PM
cnbc.com logoEli Lilly raised prices on 9 drugs last week - CNBC
www.cnbc.com - May 10 at 12:49 PM
finance.yahoo.com logoLeigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications
finance.yahoo.com - May 10 at 12:49 PM
finance.yahoo.com logoEli Lilly raised prices on 9 drugs last week
finance.yahoo.com - May 10 at 12:49 PM
finance.yahoo.com logoAratana is tracking to hit canine drug milestone, fetches funds to build inventory
finance.yahoo.com - May 9 at 6:02 PM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One
finance.yahoo.com - May 9 at 12:00 PM
americanbankingnews.com logoFY2019 EPS Estimates for Eli Lilly and Co (LLY) Decreased by SunTrust Banks
www.americanbankingnews.com - May 9 at 11:52 AM
americanbankingnews.com logoEli Lilly and Co (LLY) Expected to Announce Earnings of $1.03 Per Share
www.americanbankingnews.com - May 8 at 11:53 PM
americanbankingnews.com logoEnrique A. Conterno Sells 25,000 Shares of Eli Lilly and Co (LLY) Stock
www.americanbankingnews.com - May 8 at 4:31 PM
americanbankingnews.com logoSomewhat Positive Media Coverage Very Likely to Affect Eli Lilly and (LLY) Stock Price
www.americanbankingnews.com - May 5 at 11:45 PM
finance.yahoo.com logoEli Lilly and Company -- Moody's assigns A2 to Eli Lilly's notes; stable outlook
finance.yahoo.com - May 4 at 6:27 PM
americanbankingnews.com logoZacks: Analysts Expect Eli Lilly and Co (LLY) to Post $1.03 Earnings Per Share
www.americanbankingnews.com - May 4 at 1:37 AM
finance.yahoo.com logoLilly to Participate in UBS Global Healthcare Conference
finance.yahoo.com - May 3 at 5:25 PM
finance.yahoo.com logoIs Eli Lilly & Co.’s Valuation Higher Than Its Peers?
finance.yahoo.com - May 3 at 8:56 AM
americanbankingnews.com logoEli Lilly and (LLY) Receives News Sentiment Score of 0.10
www.americanbankingnews.com - May 2 at 11:52 PM
finance.yahoo.com logoEli Lilly’s 1Q17 Earnings: Cialis and Other Cardiovascular Products
finance.yahoo.com - May 2 at 7:23 PM
finance.yahoo.com logoLilly Announces Webcast to Discuss Oncology Pipeline
finance.yahoo.com - May 2 at 7:23 PM
reuters.com logoBRIEF-Eli Lilly and Co sets Q2 2017 dividend of $0.52 per share - Reuters
www.reuters.com - May 2 at 2:21 PM
americanbankingnews.com logoEli Lilly and Co (LLY) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 1 at 9:20 PM
americanbankingnews.com logoEli Lilly and Co (LLY) Plans $0.52 Quarterly Dividend
www.americanbankingnews.com - May 1 at 7:20 PM
baystreet.ca logoEli Lilly Hails Dividends to Follow Earnings News
www.baystreet.ca - May 1 at 5:23 PM
reuters.com logoBRIEF-Eli Lilly and Co sets Q2 2017 dividend of $0.52 per share
www.reuters.com - May 1 at 5:23 PM
finance.yahoo.com logoEli Lilly’s 1Q17 Earnings: Humalog and Other Endocrine Products
finance.yahoo.com - May 1 at 5:23 PM

Social

Chart

Eli Lilly and Co (LLY) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff